The United Kingdom and the United States have secured a key bilateral deal that will maintain zero levies on UK medicine exports being sold in the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has committed to raise funding on medicines through the National Health Service (NHS). This commitment guarantees that tariffs on these vital products will be held at nothing for a duration of the next three years.
This deal is in response to previous threats to dramatically increase duties on branded pharmaceutical products, with increases floated reaching double the cost.
"This agreement between the UK bolsters the international landscape for innovative medicines and establishes long-overdue equity to U.S.–U.K. medicine commerce," a release said.
Economic Significance
Pharmaceuticals are one of the UK's biggest export categories to the United States, which is easily the primary market for leading British pharmaceutical firms.
Export figures indicate that in the 12 months to the end of the third quarter, the UK exported drugs valued at billions to the US. This figure accounted for a significant portion of all goods exports in that period.
"This agreement secures jobs, stimulates capital expenditure and paves the way for the UK to become a global hub for medical research," the Business and Trade Secretary remarked.
Key UK Commitments
The pact entails several specific pledges from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to double total NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The sum manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates were more than twenty percent.
Industry Background
This agreement comes amid a ongoing row between the drug companies and the UK government over medicine costs and regulatory access.
The disagreement were heightened by claims that American patients were charged several times more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.
